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Background: Cardiac surgery is frequently complicated by an acute vascular lung injury and this may be mediated,
at least in part, by the (soluble) receptor for advanced glycation end products (sRAGE).
Methods: In two university hospital intensive care units, circulating sRAGE was measured together with the
68Gallium-transferrin pulmonary leak index (PLI), a measure of pulmonary vascular permeabiliy, in 60 consecutive cardiac
surgery patients stratified by the amount of blood transfusion, within 3 hours of admission to the intensive care.
Results: Cardiac surgery resulted in elevated plasma sRAGE levels compared to baseline (315 ± 181 vs 110 ± 55 pg/ml,
P = 0.001). In 37 patients the PLI was elevated 50% above normal. The PLI correlated with sRAGE (r2 = 0.11, P = 0.018).
Plasma sRAGE discriminated well between those with an elevated PLI and those with a normal PLI (area under the
operator curve 0.75; P = 0.035; 95% CI 0.55-0.95), with 91% sensitivity but low specificity of 36% at a cutoff value of
200 pg/mL. Blood transfusion did not influence sRAGE levels.
Conclusions: sRAGE is elevated in plasma after cardiac surgery and indicates increased pulmonary vascular permeability.
The level of sRAGE is not affected by transfusion.
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Cardiac surgery is frequently complicated by acute lung
injury (ALI) which, together with postoperative atelectasis,
may prolong length of stay in the intensive care unit
(ICU) [1]. ALI following cardiac surgery may be associated
with trauma, use of cardiopulmonary bypass, blood
transfusions, mechanical ventilation and others [1,2].
The pulmonary leak index (PLI) can be used as a measure
of alveolocapillary permeability, which plays a pivotal role
in the pathogenesis of ALI/acute respiratory distress
syndrome (ARDS) in critically ill patients [3], for instance
after cardiac surgery [4].* Correspondence: p.r.tuinman@amc.uva.nl
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reproduction in any medium, provided the orThe mechanism for endothelial changes in increased
alveolocapillary permeability after cardiac surgery remains
unknown. The receptor for advanced glycation end prod-
ucts (RAGE) is a multi-ligand cell-surface receptor, that
may be involved in alveolocapillary inflammation [5]. Some
of its ligands form in the presence of hyperglycaemia
or oxidant stress and are termed advanced glycation
endproducts (AGE). RAGE-ligand interactions propa-
gate inflammatory responses [6]. RAGE is expressed in
systemic vascular endothelium and nervous tissues,
but the highest basal levels of RAGE are displayed by
alveolar epithelial type 1 cells [7]. Accordingly, soluble
RAGE (sRAGE) has been postulated as a potential
plasma marker of type I cell injury [8-11]. In ALI,
sRAGE is released into the alveolar and plasma com-
partments [8] and high circulating levels are associated
with severe ALI/ ARDS [9,10]. Also, cardiopulmonary
bypass is associated with elevated plasma sRAGE levels
[12], as is blood transfusion [11]. AGEs may form inal Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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endothelial cells, resulting in oxidative damage in vitro [13].
To elucidate the mechanistic role of sRAGE in alveo-
locapillary injury after cardiac surgery, we hypothesized
that plasma sRAGE elevation following cardiac surgery
is associated with increased pulmonary vascular leakage.
Additionally, we investigated the role of blood transfusion
as a determinant of plasma sRAGE.
Methods
Setting
The study is a secondary analysis of samples from a pro-
spective case–control study (Medical Ethical Commission
Academic Medical Center, Amsterdam, The Netherlands,
MEC07/098#07.17.0539) in the mixed medical-surgical
ICUs of two university hospitals in The Netherlands per-
formed in 2006–2009 [14]. With approval from the ethical
committee, patients 18 years or older were asked written
informed consent for participation in the study prior to
valvular and/or coronary artery surgery. Exclusion criteria
were off-pump surgery, emergency surgery and the use of
immunosuppressive drugs.
Design
For PLI measurements, a nested case-cohort study was
performed. Cardiac surgery patients were included for
analysis after they had received no blood product trans-
fusion perioperatively (n = 20), a limited transfusion
regimen of 1–2 transfusions (n = 20) or multiple trans-
fusions (> 2 units of red blood cells, 2 units of fresh
frozen plasma (FFP) and 1 unit of platelets pooled
from 5 donors (n = 20). Blood samples were taken before
surgery and within 3 hours post operatively. In these 60
patients, within 3 hours post operatively, a PLI measure-
ment and non-directed bronchoalveolar lavage (NBL)
were performed.
Cardiothoracic surgery/anesthesia procedures
Patients were anesthetized according to local protocol,
with lorazepam, etomidate, sufentanil, and rocuronium
for induction of anesthesia and sevoflurane plus propofol
for maintainance of anesthesia. Steroids were given at
the discretion of the cardio-anesthesiologist. As part of
standard care, a pulmonary artery catheter was inserted
for peri-operative monitoring. In all patients, cardiopul-
monary bypass was performed under mild to moderate
hypothermia (28°C-34°C), using a membrane oxygenator
and a non-pulsatile blood flow. During the procedure,
lungs were deflated. After the procedure, all patients
were transferred to the ICU with mechanical ventilation
using a pressure controlled mode with tidal volumes
targeted at 6 ml/kg and positive end-expiratory pressure
(PEEP). In the ICU adaptive support ventilation was used
for automatic weaning in the postoperative phase. Redblood cells were transfused to maintain the haemoglobin
concentration above 5.0 mmol/L (8.7 g/dL), Platelets and
FFP were transfused in the case of (suspected) bleeding.
Transfusions administered in the operation room or
within the first 3 hours postoperatively were included
in the analysis.
Patient data collection
Potential risk factors for ALI (and therefore an increased
PLI) were scored, including diabetes, smoking and alcohol
abuse. Some known risk factors for ALI, such as pneumo-
nia, trauma and sepsis were not taken into account as the
patients included were elective surgery patients. For this
reason, presence of such a risk factor was a reason to
cancel surgery in these patients. Also, cardiopulmonary
function was scored. Data on operation-time, clamp-time
and hours of mechanical ventilation on the ICU were
recorded in the electronic patient data system. Cardiogenic
pulmonary edema was identified when pulmonary arterial
occlusion pressure was > 18 mmHg (during the study
period all patients received a pulmonary artery catheter
pre-operatively). Chest radiographs routinely taken before
surgery and on arrival at the ICU were scored for the pres-
ence of new onset bilateral interstitial abnormalities by two
independent physicians who were blinded to the predictor
variables. Left ventricular function was categorized as pre-
served (ejection fraction (EF) > 45%) or reduced (EF ≤ 45%),
from pre-operative routine echocardiograms.
Pulmonary leakage index (PLI)
For the measurement of the PLI, as described previously
[15], transferrin was labelled in vivo, after i.v. injection
of 67Gallium (Ga)-citrate, 4 to 5 MBq (physical half-life
78 h; Mallinckrodt Diagnostica, Petten, The Netherlands).
Patients were in the supine position and two scintillation
detection probes (Eurorad C.T.T., Strasburg, France) were
positioned over the right and left lung apices. Starting
at the time of the i.v. injection of 67Ga, radioactivity
was detected during 30 min. The 67Ga counts are cor-
rected for background radioactivity, physical half-life,
spillover of 67Ga, obtained by in vitro measurement of
67Ga, and expressed as cpm per lung field. At 0, 5, 8,
12, 16, 20, 25 and 30 min after 67Ga injection, blood
samples (2 ml aliquots) were taken. Each blood sample
was weighed and radioactivity was determined with a
single-well well-counter (LKB Wallac 1480 WIZARD,
Perkin Elmer, Life Science, Zaventem, Belgium), taking
background, spillover of 67Ga and decay into account.
Results are expressed as cpm g–1. For each blood sam-
ple, a time-matched cpm over each lung was taken.
The radioactivity ratio was calculated as (67Galung)/
(67Gablood) and plotted against time. The PLI was cal-
culated from the slope of increase of the radioactivity
ratio divided by the intercept, to correct for physical
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transport rate of 67Ga-transferrin from the intravascular
to the extravascular space of the lungs and is therefore a
measure of pulmonary vascular permeability. The values
for both lung fields are averaged. The upper limit normal
for the PLI is 14.7x10–3 min–1 and the measurement error
is ~10%.
Non-directed bronchoalveolar lavage technique
Non-directed bronchoalveolar lavage was performed by
instilling 20 ml of sterile 0.9% saline via a standard
50 cm, 14 gauge tracheal suction catheter as described
previously [16,17]. In short, the distal end of the catheter
was introduced via the endotracheal tube and advanced
until significant resistance was encountered. Immediately
after instillation over 10–15 seconds, fluid was aspirated
before withdrawal of the catheter. Generally, 5–10 ml of
fluid was recovered.
Assays
BALF and blood samples were centrifuged and stored
at −80°C until assays were performed. In plasma and
BALF, levels of sRAGE were determined by an ELISA
developed in our laboratory [18]. In short, 96-well plates
were coated overnight with mouse anti-human RAGE
antibody (R&D systems, Minneapolis, Minnesota, USA).
Samples diluted as appropriate were added and incu-
bated for 2 hours. Next, biotinylated goat anti-human
RAGE antibody (R&D Systems) was added and incu-
bated for another 2 hours. Streptavidin poly-HRP was
added for 30 minutes. Finally, sodium-acetate buffer
(pH 5.5) containing 100 microg/ml tetramethylbenzidine
and 0.003% H₂0₂ was added and the colour reaction
was stopped by MH₂SO₄. All measurements were made
in duplicate.
Statistical analysis
Data were checked for distribution by Kolmogorov-
Smirnov test. Normally distributed data were analyzed
using Students t test. Non-parametric data were analyzed
with Mann–Whitney U test. Categorical data were analyzed
with the chi-square test. Linear correlation coefficients are
reported where appropriate by Spearman correlation. To
evaluate independent causal factors for an increase in
PLI, a binary logistic regression analysis, using the Enter
method, was applied. Statistically and/or clinically relevant
factors were added to the model. The model was evaluated
using Hosmer-Lemeshow goodness-of-fit test.
Data are reported as mean (± SD) or median (IQR) when
appropriate. Receiver-operating-characteristic (ROC) curve
was determined, the area under the curve and sensitivity
and specificity derived. Statistical significance was defined
as P < 0.05 and exact P values are given unless <0.001.
Statistical analysis was performed with SPSS 18.0Results
Patient characteristics
Patients’ baseline and peri-operative characteristics are
given in Table 1. Surgery was uneventful in all patients,
without the need for rethoracotomy.
PLI and sRAGE
Cardiac surgery resulted in an elevated PLI with a mean
of 30 ± 18 (normal value < 14.1) x 10-3 min-1. In addition,
postoperative plasma sRAGE levels were increased
compared to baseline (Figure 1A). Levels of sRAGE did
not differ according to stratification by the number of
blood transfusions (Figure 1B). Following surgery, levels of
sRAGE in BALF were more than 10-fold lower than in
plasma (12 (15) vs 287 (192) pg/mL). Patients were ar-
bitrarily divided in a group with a strongly elevated PLI
(>1.5 x upper limit of normal) and a less elevated PLI
(<1.5 x upper limit of normal). The group with high PLI
had a lower PaO₂/FiO₂-ratio than the group with lower
PLI (Table 1). Patients with a more elevated PLI had a
longer duration of surgery, but not of clamp- and pump
time. Patients with a strongly elevated PLI (>1.5 x upper
limit of normal) had a higher level of sRAGE in plasma
compared to those with a less elevated PLI (Figure 2). The
levels of sRAGE in BALF did not differ between patients
with a strongly elevated or less elevated PLI. There was a
small but positive relation between plasma sRAGE and PLI
(r 0.32, r2 = 0.11, P = 0.018) (Additional file 1: Figure S3).
The area under the curve of the ROC-curve applied to
plasma sRAGE and PLI was 0.75 (P = 0.035; 95% CI
0.55-0.95), which represents acceptable discrimination
(Additional file 2: Figure S4). For plasma sRAGE, a cut-off
value of 200 pg/mL was found to have a good sensitivity
of 91% but low specificity of 36% for an elevated PLI.
For exploration of confounding variables, a logistic
regression analysis was performed. Besides sRAGE,
operation-time, EuroSCORE and amount of blood
products were added to the model. Analysis showed
that sRAGE and operation time were risk factors for a
strongly increased PLI (Table 2). Of note, an OR of
1.005 for sRAGE applies to each increment of 1 pg/ml.
Thereby, a patient with an sRAGE level of 190 pg/mL
(which is the median increase in sRAGE in this population)
has an OR of 2.59 (95% CI 1.47-3.71) for an increased PLI.
Patients with bilateral pulmonary changes on chest X-ray
at admission to the ICU (n = 5) had a significant lower
P/F ratio compared to patients without these changes
(n = 54) (188 (60) vs 315 (105), P = 0.025), as expected.
In addition, in these patients levels of BALF sRAGE
were elevated compared to patients with non-significant
pulmonary changes on chest X-ray (97 (168) vs 18 (21)
pg/mL, P <0.001). Also, PLI was more elevated in these
patients (45 (30) vs 28 (16) x 10-3 min-1, P =0.050). As
groups differed in operation time, which may be a
Table 1 Demographic and peri-operative characteristics







Age, yearsΦ 66 (±14) 71 (±8.5) 0.43
Sex, male† 19 (82) 25 (68) 0.12
EuroSCOREΦ 4.9 (±3.2) 7.3 (±1.5) 0.45
ASA-scoreΦ 2.7 (±0.6 2.3 (±1.2) 0.67
Diabetes mellitus† 4 (17) 6 (16) 0.82
COPD† 2 (9) 3 (8) 0.87
Left ventricular function† 0.65
Reduced 8 (35) 10(27)
Preserved 15 (65) 23 (62)
FEV1Φ 80 (±34) 103 (±20) 0.16
Surgery data
CABG† 15 (65) 15 (40) 0.06
Valve replacement† 1 (4) 9 (24) 0.09
Other type of surgery† 7 (30) 13 (35) 0.27
Clamp time, minΦ 77 (±35) 87 (±29) 0.20
Pump time, minΦ 114 (±48) 114 (±33) 0.26
Operation-time, minΦ 292 (±81) 333 (±27) 0.02
Perioperative data
Red blood cells, unitsΦ 1.5 (±3.4) 2.7 (±3.2) 0.36
Fresh frozen plasma, unitsΦ 1.2 (± 2.4) 1.2 (±2.1) 0.93
Platelets, unitsΦ 0.4 (±0.6) 0.6 (±0.8) 0.13
Postoperative data
CVP, mmHgΦ 11 (±5) 12 (±6) 0.35
Cardiac output, liters/min# 5.1 (1.1) 4.3 (0.3) 0.23
Mechanical ventilation, hoursΦ 11.7 (±6.2) 16.9 (±25.8) 0.33
PaO₂/FiO₂ ratio# 336 (162) 280 (112) 0.02
PLI was dichotomized into strongly elevated and modestly elevated, at a
cut-off of 1.5 x elevated above upper limit of normal. EuroSCORE: European
System for Cardiac Operative Risk Evaluation; ASA-score: physical status
classification system according to the American Society of Anesthesiologists;
FEV1: forced expiratory volume in 1 second, given in% of predicted; CVP:
central venous pressure, measured at time of PLI measurement; Cardiac output
and PaO2/FiO2 ratio idem;
Data are presented in †counts (percents), Φmean (±SD) or in #median (IQR)
when appropriate.












































Figure 1 A: Levels of sRAGE in plasma before and after cardiac
surgery. B: Levels of sRAGE in plasma BALF after surgery according
to amount of transfused products. Non: non-transfused patients;
Limited: 1–2 units of blood transfused; Multiple: ≥ 5 units of
blood transfused. *** P < 0.001. Data are presented as median +
interquartile range.
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divided according to median operation time and re-
analyzed. No difference was found in the median level of
plasma sRAGE stratified for operation time (267 (205) vs
298 (201) pg/ml. resp., P = 0.191).
Discussion
This study suggests that sRAGE levels, a biomarker of
pulmonary tissue damage, are elevated in plasma after car-
diac surgery and may serve as an indicator of pulmonaryvascular injury, independent of blood product transfu-
sion. Although sRAGE levels are increased after car-
diac surgery, a mediating role of endogenous AGES in
alveocapillary inflammation cannot be concluded from
our results altogether.
Plasma levels of sRAGE were enhanced after lung trans-
plantation and in ALI/ARDS, and directly associated with
a poor clinical outcome [8,10]. In addition, an increase in
plasma sRAGE was found in cardiac surgery patients after
cardiopulmonary bypass [12]. We now demonstrate that
sRAGE is linked to increased pulmonary capillary perme-
ability and a decrease in oxygenation, suggesting a possible
mediator role in lung injury after cardiac surgery. The
higher plasma sRAGE levels were associated with a
more elevated PLI, which is an established early marker
of increased capillary permeability in the lung [15], so that
the elevated plasma sRAGE and PLI may both reflect
endothelial injury in the lungs occurring during cardiac
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Figure 2 sRAGE in plasma and BALF after cardiac surgery in
patients with a pulmonary leakage index (PLI) of ≤ 1.5 or > 1.5
times the upper limit of normal (< 14.1 x 10-3 min-1); *P =0.038.
Data are presented as median + interquartile range.
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found in our study may be specific for cardiac surgery pa-
tients, since sRAGE was recently found not to be predictive
of lung injury in other critically ill patients [20]. However,
our results are in line with a previous study in children
which found plasma sRAGE to enable prediction of acute
lung injury after cardiac surgery [21]. We hypothesize that
during progression of lung injury, sRAGE production by al-
veolar cells may become more prominent and higher levels
of sRAGE in BALF may be found as suggested before [8],
since we found higher levels of sRAGE in BALF in patients
with marked pulmonary findings on chest X-ray. In line
with reflecting lung vascular injury, patients with a more el-
evated PLI had a lower PaO₂/FiO₂ ratio and longer duration
of mechanical ventilation.
In contrast to the association between the volume of
blood transfused and the plasma levels of sRAGE [11],
we did not observe a relation between blood product
transfusion and sRAGE, suggesting that upregulationTable 2 Logistic regression analysis of risk factors in
cardiac surgery patients for an increased pulmonary
leakage index > 1.5 times the upper limit of normal
Risk factors OR (95%) p Value
sRAGE, pg/mL 1.005 (1.00-1.01) 0.039
Operation time, min 1.010 (1.00-1.02) 0.030
EuroSCORE 1.090 (0.88-1.36) 0.441
Total amount of transfusions, units 0.968 (0.86-1.09) 0.579
PLI was dichotomized into strongly elevated and modestly elevated, at a
cut-off of 1.5 x elevated above upper limit of normal. (14.1 x 10-3 min-1).
sRAGE: soluble receptor for advanced glycation end products; EuroSCORE:
European System for Cardiac Operative Risk Evaluation.and shedding of the receptor in pulmonary endothe-
lium was caused by endogenously released AGE. Con-
versely, the use of cardiopulmonary bypass elevating
sRAGE may have been instrumental, as suggested be-
fore [11,12,22]. Alternatively, the rise in plasma sRAGE
may be a reflection of alveolar epithelial cell injury,
possibly caused in part by deflation of the lungs during
surgery. Since in our patients plasma levels were 10-fold
higher then in BALF, a systemic production of sRAGE
seems more likely then alveolar sRAGE production in this
study, unless mainly involving pulmonary endothelium and
intravascular shedding. Of note, one must take into account
that the BALF samples are diluted to some account.
This study may have implications for future efforts to
decrease lung injury following cardiac surgery. Previous
experimental data suggest that sRAGE may neutralize
the ligand-mediated damage by acting as a decoy, thus
protecting sensitive cells from the deleterious effects of
ligand-RAGE hyperactivity [23,24]. In line, blocking of
RAGE-ligand interaction by recombinant sRAGE was
protective in murine models of lung injury [25] and ische-
mic heart injury [26]. Furthermore, determining sRAGE
early in the course of lung injury may be of therapeutic
significance, because patients with higher sRAGE levels
have been shown to benefit the most from lung protective
mechanical ventilation [9]. Our results contribute to the
rationale of exploring the therapeutic potential of RAGE
as an interventional target in patients at risk of developing
ALI/ARDS.
This study has several potential limitations. Although
we corrected for possible confounding by performing a
logistic regression analysis and by dividing patients accord-
ing to operation time, we can not exclude confounders
unaccounted for. In addition, we performed an in house
ELISA and levels were about 4 times lower than those
measured in studies using commercially available kits [12].
However, levels were comparable to a previous study in our
centre [18]. Furthermore, a comparison of sRAGE to other
biomarkers of lung injury (for example surfactant protein
B, which leaks in the bloodstream because of alveolar-
capillary damage) [27], would have strengthened our data.Conclusions
sRAGE is elevated in plasma after cardiac surgery and
indicates increased pulmonary vascular permeability. The
level of sRAGE is not affected by transfusion.Additional files
Additional file 1: Figure S3. The receiver operating curve of the ability
of sRAGE plasma levels after cardiac surgery to predict the development
of a strongly increased pulmonary leakage index of > 1.5 times the upper
limit of normal (< 14.1 x 10-3 min-1).
Tuinman et al. BMC Pulmonary Medicine 2013, 13:76 Page 6 of 7
http://www.biomedcentral.com/1471-2466/13/76Additional file 2: Figure S4. Scatterplot of the relation between
pulmonary leakage index (PLI) and plasma levels of soluble receptor of
advanced glycation end products (sRAGE).Abbreviations
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